v3.20.4
Segments of Business and Geographic Areas
 12 Months Ended
Jan. 03, 2021
Segment Reporting [Abstract]  
Segments of Business and Geographic Areas Segments of Business* and Geographic Areas
 Sales to Customers % Change
(Dollars in Millions)202020192018’20 vs. ’19’19 vs. ’18
Consumer Health)(1)
   
OTC
     U.S.$2,460 2,010 1,850 22.4 %8.6 
     International2,364 2,434 2,484 (2.9)(2.0)
     Worldwide 4,824 4,444 4,334 8.5 2.5 
Skin Health/Beauty(2)
     U.S.2,350 2,392 2,403 (1.7)(0.4)
     International2,100 2,201 1,979 (4.6)11.2 
     Worldwide 4,450 4,593 4,382 (3.1)4.8 
Oral Care
     U.S.683 621 637 9.9 (2.5)
     International958 906 918 5.7 (1.2)
     Worldwide 1,641 1,528 1,555 7.4 (1.7)
Baby Care
     U.S.376 362 422 3.7 (14.2)
     International1,141 1,313 1,436 (13.1)(8.6)
     Worldwide 1,517 1,675 1,858 (9.4)(9.9)
Women's Health
     U.S.13 12 13 8.2 (5.5)
     International888 974 1,036 (8.8)(6.0)
     Worldwide 901 986 1,049 (8.6)(6.0)
Wound Care/Other
     U.S.480 441 436 8.9 1.2 
     International240 230 239 4.1 (3.9)
     Worldwide 720 671 675 7.2 (0.6)
TOTAL CONSUMER HEALTH
     U.S.6,362 5,839 5,761 9.0 1.4 
     International7,691 8,059 8,092 (4.6)(0.4)
     Worldwide 14,053 13,898 13,853 1.1 0.3 
(1)Previously referred to as Consumer
(2)Previously referred to as Beauty
PHARMACEUTICAL
Immunology
     U.S.10,175 9,641 9,073 5.5 6.3 
     International4,880 4,309 4,047 13.2 6.5 
     Worldwide 15,055 13,950 13,120 7.9 6.3 
     REMICADE®
     U.S.2,508 3,079 3,664 (18.5)(16.0)
     U.S. Exports346 294 436 18.0 (32.7)
     International893 1,007 1,226 (11.4)(17.8)
     Worldwide 3,747 4,380 5,326 (14.4)(17.8)
     SIMPONI / SIMPONI ARIA®
     U.S.1,155 1,159 1,051 (0.3)10.2 
     International1,088 1,029 1,033 5.8 (0.4)
     Worldwide 2,243 2,188 2,084 2.6 5.0 
     STELARA®
     U.S.5,240 4,346 3,469 20.6 25.3 
     International2,467 2,015 1,687 22.4 19.4 
     Worldwide 7,707 6,361 5,156 21.1 23.4 
     TREMFYA®
     U.S.926 764 453 21.3 68.5 
     International421 248 91 69.9 **
     Worldwide 1,347 1,012 544 33.2 85.9 
     OTHER IMMUNOLOGY
     U.S.— — — — —
     International11 10 10 6.4 4.5 
     Worldwide 11 10 10 6.4 4.5 
Infectious Diseases
     U.S.1,735 1,597 1,378 8.6 15.9 
     International1,839 1,815 1,926 1.3 (5.7)
     Worldwide 3,574 3,413 3,304 4.7 3.3 
     EDURANT® / rilpivirine
     U.S.44 50 58 (11.2)(13.7)
     International920 812 758 13.3 7.1 
     Worldwide 964 861 816 11.9 5.6 
     PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA®
     U.S.1,587 1,422 1,169 11.6 21.6 
     International597 689 786 (13.4)(12.3)
     Worldwide 2,184 2,110 1,955 3.5 8.0 
     OTHER INFECTIOUS DISEASES
     U.S.104 126 151 (17.6)(16.5)
     International323 315 382 2.6 (17.6)
     Worldwide 427 441 533 (3.2)(17.3)
Neuroscience
     U.S.3,091 2,919 2,574 5.9 13.4 
     International3,457 3,409 3,503 1.4 (2.7)
     Worldwide 6,548 6,328 6,077 3.5 4.1 
     CONCERTA® / methylphenidate
     U.S.183 233 229 (21.4)1.7 
     International439 463 434 (5.1)6.6 
     Worldwide 622 696 663 (10.6)4.9 
     INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA®
     U.S.2,314 2,107 1,791 9.8 17.6 
     International1,339 1,224 1,137 9.4 7.7 
     Worldwide 3,653 3,330 2,928 9.7 13.7 
     RISPERDAL CONSTA®
     U.S.296 314 315 (5.9)(0.3)
     International346 374 422 (7.5)(11.4)
     Worldwide 642 688 737 (6.8)(6.7)
     OTHER NEUROSCIENCE
     U.S.298 266 239 12.4 11.4 
     International1,334 1,349 1,510 (1.1)(10.7)
     Worldwide 1,632 1,614 1,749 1.1 (7.7)
Oncology
     U.S.5,092 4,299 4,331 18.5 (0.7)
     International7,275 6,393 5,513 13.8 16.0 
     Worldwide 12,367 10,692 9,844 15.7 8.6 
     DARZALEX®
     U.S.2,232 1,567 1,203 42.4 30.3 
     International1,958 1,430 822 36.9 73.9 
     Worldwide 4,190 2,998 2,025 39.8 48.0 
     ERLEADA®
     U.S.58329712496.1 **
     International17635—  * ***
     Worldwide760332124 * ***
     IMBRUVICA®
     U.S.1,821 1,555 1,129 17.1 37.7 
     International2,307 1,856 1,486 24.3 24.9 
     Worldwide 4,128 3,411 2,615 21.0 30.4 
     VELCADE®
     U.S.— — — — — 
     International408 751 1,116 (45.7)(32.7)
     Worldwide 408 751 1,116 (45.7)(32.7)
     ZYTIGA® /abiraterone acetate
     U.S.373 810 1,771 (54.0)(54.3)
     International2,097 1,985 1,727 5.6 15.0 
     Worldwide 2,470 2,795 3,498 (11.6)(20.1)
     OTHER ONCOLOGY
     U.S.83 70 104 19.2 (32.7)
     International330 336 362 (1.9)(7.2)
     Worldwide 413 407 466 1.7 (12.7)
Pulmonary Hypertension
     U.S.2,133 1,684 1,651 26.6 2.0 
     International1,015 939 922 8.2 1.9 
     Worldwide 3,148 2,623 2,573 20.0 1.9 
     OPSUMIT®
     U.S.1,008 766 700 31.7 9.4 
     International631 562 515 12.3 9.0 
     Worldwide 1,639 1,327 1,215 23.5 9.2 
     UPTRAVI®
     U.S.955 714 598 33.8 19.3
     International138 105 65 30.9 62.4
     Worldwide 1,093 819 663 33.5 23.5
     OTHER
     U.S.169 205 353 (17.6)(41.9)
     International247 272 342 (9.2)(20.5)
     Worldwide 416 476 695 (12.8)(31.5)
Cardiovascular / Metabolism / Other
     U.S.3,509 3,734 4,279 (6.0)(12.7)
     International1,369 1,458 1,537 (6.1)(5.2)
     Worldwide 4,878 5,192 5,816 (6.0)(10.7)
     XARELTO®
     U.S.2,345 2,313 2,477 1.4 (6.6)
     International— — — — — 
     Worldwide 2,345 2,313 2,477 1.4 (6.6)
     INVOKANA® / INVOKAMET®
     U.S.564 536 711 5.2 (24.6)
     International231 199 170 16.3 17.3 
     Worldwide 795 735 881 8.2 (16.5)
     PROCRIT® / EPREX®
     U.S.277 505 674 (45.1)(25.1)
     International274 285 314 (3.8)(9.2)
     Worldwide 552 790 988 (30.2)(20.0)
     OTHER
     U.S.323 380 417 (15.1)(9.1)
     International864 974 1,053 (11.3)(7.6)
     Worldwide 1,186 1,353 1,470 (12.4)(8.0)
TOTAL PHARMACEUTICAL
     U.S.25,735 23,874 23,286 7.8 2.5 
     International19,837 18,324 17,448 8.3 5.0 
     Worldwide 45,572 42,198 40,734 8.0 3.6 
 
MEDICAL DEVICES
Diabetes Care
     U.S.— — 371 — **
     International— — 638 — **
     Worldwide — — 1,009 — **
Interventional Solutions
     U.S.1,452 1,443 1,283 0.6 12.5 
     International1,594 1,554 1,363 2.6 14.0 
     Worldwide 3,046 2,997 2,646 1.6 13.3 
Orthopaedics
     U.S.4,779 5,319 5,281 (10.2)0.7 
     International2,984 3,520 3,604 (15.2)(2.3)
     Worldwide 7,763 8,839 8,885 (12.2)(0.5)
     HIPS
     U.S.793 863 841 (8.2)2.6 
     International487 575 577 (15.3)(0.3)
     Worldwide 1,280 1,438 1,418 (11.0)1.4 
     KNEES
     U.S.743 889 911 (16.4)(2.4)
     International427 591 591 (27.8)0.0 
     Worldwide 1,170 1,480 1,502 (21.0)(1.4)
     TRAUMA
     U.S.1,648 1,652 1,599 (0.2)3.3 
     International966 1,068 1,100 (9.6)(2.9)
     Worldwide 2,614 2,720 2,699 (3.9)0.8 
     SPINE, SPORTS & OTHER(3)
     U.S.1,595 1,915 1,930 (16.7)(0.8)
     International1,104 1,286 1,336 (14.1)(3.8)
     Worldwide 2,699 3,201 3,266 (15.7)(2.0)
Surgery
     U.S.3,249 3,828 4,125 (15.1)(7.2)
     International4,983 5,673 5,776 (12.2)(1.8)
     Worldwide 8,232 9,501 9,901 (13.4)(4.0)
     ADVANCED
     U.S.1,535 1,637 1,657 (6.2)(1.2)
     International2,304 2,458 2,345 (6.2)4.8 
     Worldwide 3,839 4,095 4,002 (6.2)2.3 
     GENERAL
     U.S.1,714 2,192 2,468 (21.8)(11.2)
     International2,679 3,215 3,431 (16.7)(6.3)
     Worldwide 4,392 5,406 5,899 (18.8)(8.4)
Vision
     U.S.1,557 1,794 1,777 (13.2)0.9 
     International2,362 2,830 2,776 (16.5)2.0 
     Worldwide 3,919 4,624 4,553 (15.2)1.6 
     CONTACT LENSES / OTHER
     U.S.1,213 1,304 1,237 (7.0)5.4 
     International1,781 2,088 2,065 (14.7)1.1 
     Worldwide 2,994 3,392 3,302 (11.7)2.7 
     SURGICAL
     U.S.344 490 540 (29.7)(9.4)
     International581 742 711 (21.7)4.4 
     Worldwide 925 1,232 1,251 (24.9)(1.6)
TOTAL MEDICAL DEVICES   
     U.S.11,036 12,384 12,837 (10.9)(3.5)
     International11,923 13,579 14,157 (12.2)(4.1)
     Worldwide 22,959 25,963 26,994 (11.6)(3.8)
WORLDWIDE   
     U.S.43,133 42,097 41,884 2.5 0.5 
     International39,451 39,962 39,697 (1.3)0.7 
     Worldwide $82,584 82,059 81,581 0.6 %0.6 
(3)Previously referred to as Spine & Other
*Certain prior year amounts have been reclassified to conform to current year presentation
**Percentage greater than 100% or not meaningful

 Income (Loss) Before TaxIdentifiable Assets
(Dollars in Millions)
2020 (3)
2019 (4)
2018 (5)
20202019
Consumer Health$(1,064)2,061 2,320 $27,355 26,618 
Pharmaceutical15,462 8,816 12,568 66,158 56,292 
Medical Devices3,044 7,286 4,397 49,578 49,462 
Total17,442 18,163 19,285 143,091 132,372 
Less: Expense not allocated to segments (1)
945 835 1,286 
General corporate (2)
31,803 25,356 
Worldwide total$16,497 17,328 17,999 $174,894 157,728 

Additions to Property,
Plant & Equipment		Depreciation and
Amortization
(Dollars in Millions)202020192018202020192018
Consumer Health$248 328 438 $785 765 688 
Pharmaceutical863 950 1,012 4,006 3,910 3,802 
Medical Devices1,980 1,912 1,843 2,140 2,014 2,103 
Segments total3,091 3,190 3,293 6,931 6,689 6,593 
General corporate256 308 377 300 320 336 
Worldwide total$3,347 3,498 3,670 $7,231 7,009 6,929 
 Sales to Customers
Long-Lived Assets (6)
(Dollars in Millions)20202019201820202019
United States$43,133 42,097 41,884 $49,951 41,528 
Europe18,980 18,466 18,753 49,363 48,015 
Western Hemisphere excluding U.S. 5,335 5,941 6,113 2,734 2,862 
Asia-Pacific, Africa15,136 15,555 14,831 5,484 5,486 
Segments total82,584 82,059 81,581 107,532 97,891 
General corporate1,029 1,049 
Other non long-lived assets66,333 58,788 
Worldwide total$82,584 82,059 81,581 $174,894 157,728 
See Note 1 for a description of the segments in which the Company operates.
Export sales are not significant. In fiscal year 2020, the Company utilized three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0% and 12.0% of the total consolidated revenues. In fiscal year 2019, the Company had three wholesalers distributing products for all three segments that represented approximately 15.0%, 12.0% and 11.0% of the total consolidated revenues. In fiscal year 2018, the Company had three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0%, and 11.0% of the total consolidated revenues.
(1)Amounts not allocated to segments include interest (income) expense and general corporate (income) expense.
(2)General corporate includes cash, cash equivalents and marketable securities.
(3)Consumer Health includes:
•Litigation expense of $3.9 billion, primarily talc related reserves and certain settlements.
Pharmaceutical includes:
•Litigation expense of $0.8 billion, primarily related to the agreement in principle to settle opioid litigation
•An unrealized gain on securities of $0.5 billion
•A restructuring related charge of $0.1 billion
Medical Devices includes:
•A contingent consideration reversal of $1.1 billion related to the timing of certain developmental milestones associated with the Auris Health acquisition.
•Litigation expense of $0.3 billion
•A restructuring related charge of $0.3 billion
•An in-process research and development expense of $0.2 billion
•A Medical Device Regulation charge of $0.1 billion
(4) Consumer Health includes:
•A gain of $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO
•Litigation expense of $0.4 billion
•A restructuring related charge of $0.1 billion
Pharmaceutical includes:
•Litigation expense of $4.3 billion of which $4.0 billion is related to the agreement in principle to settle opioid litigation
•An in-process research and development expense of $0.9 billion related to the Alios asset
•A research and development expense of $0.3 billion for an upfront payment related to argenx
•An unrealized gain on securities of $0.6 billion
•Actelion acquisition and integration related costs of $0.2 billion
•A restructuring charge of $0.1 billion
Medical Devices includes:
•A gain of $2.0 billion from the divestiture of the ASP business
•A restructuring related charge of $0.4 billion
•Litigation expense of $0.4 billion
•Auris Health acquisition and integration related costs of $0.1 billion
(5) Consumer Health includes:
•A gain of $0.3 billion from the divestiture of NIZORAL®
•Litigation expense of $0.3 billion
Pharmaceutical includes:
•An in-process research and development charge of $1.1 billion related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $0.2 billion
•Actelion acquisition and integration related costs of $0.2 billion
•An unrealized loss on securities of $0.2 billion
•A gain of $0.2 billion from the divestiture of certain non-strategic Pharmaceutical products
Medical Devices includes:
•Litigation expense of $1.7 billion
•A restructuring related charge of $0.6 billion
•AMO acquisition and integration related costs of $0.1 billion
•A gain of $0.5 billion from the divestiture of the LifeScan business
(6) Long-lived assets include property, plant and equipment, net for fiscal years 2020, and 2019 of $18,766 and $17,658, respectively, and intangible assets and goodwill, net for fiscal years 2020 and 2019 of $89,795 and $81,282, respectively.